NEW YORK, March 30, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company") (NASDAQ: EGRX). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 237.
The investigation concerns whether Eagle and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On February 25, 2016, Eagle's CEO stated, regarding the pending New Drug Application ("NDA") for the Company's anticoagulant drug KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2." However, on March 18, 2016, Eagle announced that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO™.
On this news, Eagle stock fell $10.18, or 18.96%, to close at $43.50 on March 18, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Beverly Hills, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-eagle-pharmaceuticals-inc---egrx-300243403.html
SOURCE Pomerantz LLP